PT-141· 10mg
Melanocortin agonist. Libido research, central pathway.
Individual
$55.80
label.overview
Cyclic 7-amino-acid analog of α-MSH. Acts on melanocortin receptors in the CNS — the desire pathway rather than the vascular pathway.
PT-141 is FDA-approved for HSDD as Vyleesi. Onset 30–90 minutes; works centrally rather than via PDE5 inhibition.
Mechanism
MC3R / MC4R agonist (central).
Researcher notes
- • 0.5–2 mg subcutaneous, 45–60 min before activity.
- • On-demand only — maximum 2 doses per week.
Mechanism
MC3R / MC4R agonist (central).
Half-life
~2 hours
Reconstitution
Add 2 mL bacteriostatic water. Each 0.1 mL = 500 mcg.
Storage
Lyophilized: 2–8 °C. Reconstituted: 2–8 °C, use within 30 days.
Reconstitution & general research dosing
- Reconstitution
- 2 mL bacteriostatic water into a 10 mg vial → 5 mg/mL (each 0.2–0.4 mL = 1–2 mg).
- Typical research dose
- Reference 1–2 mg as-needed, 45–60 min pre-event.
- Frequency
- On-demand only — not a daily peptide.
- Vial duration
- A 10 mg vial covers ~5 doses at 2 mg and ~10 doses at 1 mg. On-demand use almost always finishes well inside the 30-day reconstituted-use window.
- Storage
- Refrigerate 2–8 °C; use within 30 days reconstituted.